Onaka (Pidotimod)

Pidotimod enhances both innate and adaptive immunity by promoting T‑lymphocyte proliferation, increasing the phagocytic activity of neutrophils and macrophages, and up‑regulating HLA‑DR expression and cytokine production, which together improve the body’s ability to fight infections.

The dosage of Onaka is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and local treatment guidelines. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for pidotimod in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Onaka, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Onaka’s active ingredient pidotimod is a synthetic dipeptide that specifically stimulates T‑cell activity and phagocytosis, whereas other immunostimulants may act through different pathways such as cytokine induction or toll‑like receptor activation. Clinical choice depends on the infection profile, patient tolerance, and physician experience.

Onaka should be stored at ambient temperature, below 25 °C, in its original packaging. It must be kept away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Onaka is taken orally. The tablet or capsule is swallowed whole with water, typically with or without food, as directed by the prescribing healthcare professional.

Serious adverse reactions, although rare, can include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, significant liver injury, and marked reductions in neutrophil counts. Patients should seek immediate medical attention if they experience symptoms like rash, difficulty breathing, jaundice, or unexplained fever.

Onaka is contraindicated in patients with known hypersensitivity to pidotimod or any excipients in the formulation. Caution is advised for individuals with severe hepatic or renal impairment, and it should be avoided in patients receiving live vaccines without medical supervision.